Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:IOVA NASDAQ:STTK NASDAQ:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$81.76+0.4%$78.51$57.33▼$99.50$1.85B0.46391,374 shs335,256 shsIOVAIovance Biotherapeutics$4.37+6.6%$3.65$1.66▼$5.63$1.83B0.6914.97 million shs12.76 million shsSTTKShattuck Labs$6.06-0.8%$6.67$0.71▼$8.33$468.52M1.18563,499 shs318,453 shsZYMEZymeworks$24.79-2.4%$25.75$11.02▼$29.75$1.85B1.2639,681 shs509,443 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.43%-0.29%+2.71%+5.98%+40.19%IOVAIovance Biotherapeutics+6.59%+23.45%+27.41%+15.30%+152.60%STTKShattuck Labs-0.82%-1.78%-21.50%+50.00%+426.96%ZYMEZymeworks-2.40%-0.20%-13.20%+4.12%+2,478,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$81.76+0.4%$78.51$57.33▼$99.50$1.85B0.46391,374 shs335,256 shsIOVAIovance Biotherapeutics$4.37+6.6%$3.65$1.66▼$5.63$1.83B0.6914.97 million shs12.76 million shsSTTKShattuck Labs$6.06-0.8%$6.67$0.71▼$8.33$468.52M1.18563,499 shs318,453 shsZYMEZymeworks$24.79-2.4%$25.75$11.02▼$29.75$1.85B1.2639,681 shs509,443 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.43%-0.29%+2.71%+5.98%+40.19%IOVAIovance Biotherapeutics+6.59%+23.45%+27.41%+15.30%+152.60%STTKShattuck Labs-0.82%-1.78%-21.50%+50.00%+426.96%ZYMEZymeworks-2.40%-0.20%-13.20%+4.12%+2,478,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 2.63Moderate Buy$107.3331.28% UpsideIOVAIovance Biotherapeutics 2.30Hold$8.4392.87% UpsideSTTKShattuck Labs 2.67Moderate Buy$13.00114.52% UpsideZYMEZymeworks 2.91Moderate Buy$38.0053.29% UpsideCurrent Analyst Ratings BreakdownLatest STTK, ZYME, ANIP, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/14/2026ANIPANI Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/8/2026STTKShattuck Labs WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $11.005/8/2026ZYMEZymeworks Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$33.00 ➝ $34.005/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.004/27/2026STTKShattuck Labs Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight4/27/2026ZYMEZymeworks Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026ZYMEZymeworks Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $18.004/15/2026ANIPANI Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/10/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$883.37M2.11$9.98 per share8.19$24.72 per share3.31IOVAIovance Biotherapeutics$263.50M7.40N/AN/A$1.62 per share2.70STTKShattuck Labs$1M464.68N/AN/A$1.25 per share4.85ZYMEZymeworks$105.96M17.08N/AN/A$2.24 per share11.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$78.34M$3.9520.709.18N/A9.98%27.51%10.02%8/14/2026 (Estimated)IOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%8/6/2026 (Estimated)STTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)ZYMEZymeworks-$81.13M-$1.37N/A77.47N/A-126.92%-37.97%-25.31%8/6/2026 (Estimated)Latest STTK, ZYME, ANIP, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/A5/7/2026Q1 2026ZYMEZymeworks-$0.10-$0.59-$0.49-$0.59$24.38 million$2.41 million3/31/2026Q4 2025ZYMEZymeworksN/A-$0.59N/A-$0.59N/A$2.41 million3/5/2026Q4 2025STTKShattuck Labs-$0.12-$0.12N/A-$0.12$0.17 million($1.00) million3/2/2026Q4 2025ZYMEZymeworks-$0.35-$0.55-$0.20-$0.55$21.78 million$2.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.063.122.52IOVAIovance BiotherapeuticsN/A3.603.15STTKShattuck LabsN/A22.0722.06ZYMEZymeworksN/A10.8210.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%IOVAIovance Biotherapeutics77.03%STTKShattuck Labs58.74%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals8.10%IOVAIovance Biotherapeutics7.80%STTKShattuck Labs8.79%ZYMEZymeworks33.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableZYMEZymeworks46073.02 million48.55 millionN/ASTTK, ZYME, ANIP, and IOVA HeadlinesRecent News About These CompaniesZymeworks: Royalty-Backed Biotech Flywheel With Underappreciated ADC OptionalityMay 22, 2026 | seekingalpha.comZymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from BrokeragesMay 18, 2026 | americanbankingnews.comVanguard Group Inc. Increases Position in Zymeworks Inc. $ZYMEMay 15, 2026 | marketbeat.comZymeworks Authorizes 2026 Share Repurchase Program, Affirms LiquidityMay 14, 2026 | tipranks.comZymeworks’ Earnings Call Balances Progress And PressureMay 14, 2026 | theglobeandmail.comZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | financialpost.comFZymeworks Announces Share Repurchase Program of up to $125 Million of its Common StockMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Insmed (INSM)May 14, 2026 | theglobeandmail.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | financialpost.comFZymeworks Announces Participation in Upcoming Investor ConferencesMay 13, 2026 | globenewswire.comZymeworks Inc. 2026 Q1 - Results - Earnings Call PresentationMay 12, 2026 | seekingalpha.comHere's What Analysts Are Forecasting For Zymeworks Inc. (NASDAQ:ZYME) After Its First-Quarter ResultsMay 11, 2026 | finance.yahoo.comA Look At Zymeworks (ZYME) Valuation After Earnings Miss And Key FDA And Capital Return UpdatesMay 9, 2026 | finance.yahoo.comZymeworks Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comZymeworks Inc. (ZYME) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comZymeworks (NASDAQ:ZYME) Trading Down 8.9% After Earnings MissMay 8, 2026 | marketbeat.comWells Fargo & Company Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) StockMay 8, 2026 | marketbeat.comZymeworks (ZYME) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comZymeworks (NASDAQ:ZYME) Posts Quarterly Earnings Results, Misses Estimates By $0.49 EPSMay 7, 2026 | marketbeat.comZymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comZymeworks Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTTK, ZYME, ANIP, and IOVA Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$81.76 +0.35 (+0.43%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$81.79 +0.03 (+0.04%) As of 05/27/2026 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Iovance Biotherapeutics NASDAQ:IOVA$4.37 +0.27 (+6.59%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$4.41 +0.04 (+0.92%) As of 05/27/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Shattuck Labs NASDAQ:STTK$6.06 -0.05 (-0.82%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$6.04 -0.01 (-0.25%) As of 05/27/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.Zymeworks NASDAQ:ZYME$24.79 -0.61 (-2.40%) Closing price 05/27/2026 04:00 PM EasternExtended Trading$24.80 +0.02 (+0.06%) As of 05/27/2026 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
